TIDMPRTC
PureTech Health PLC
16 May 2017
16 May 2017
PureTech Health plc
PureTech Health's Vedanta Biosciences Granted Three New U.S.
Patents for Therapeutics Based on
Immune-Modulating Bacterial Consortia
PureTech Health plc ("PureTech", LSE: PRTC), an advanced,
clinical-stage biopharmaceutical company, is pleased to note that
the United States Patent and Trademark Office (USPTO) has issued
three new patents to Vedanta Biosciences. The latest issuances
further strengthen Vedanta Biosciences' leading intellectual
property position, broadly covering compositions of matter and
methods of use for immune-modulating therapeutic products based on
microbiome-derived beneficial clostridium bacteria.
Bharatt Chowrira, President and Chief of Business and Strategy
at PureTech Health, said: "These new U.S. patents further
strengthen Vedanta Biosciences' leading global IP portfolio, which
includes issuances from the European Patent Office, Japan Patent
Office, and the United States Patent and Trademark Office, as well
as an exclusive, worldwide license from the University of Tokyo.
Along with our proprietary technology platform, industry leading
intellectual proprietary portfolio, robust pipeline of bacterial
consortia-based therapeutics and GMP manufacturing capabilities, we
believe Vedanta is well positioned to deliver on the promise of
microbiome-based therapeutics."
The full text of the announcement from Vedanta is as
follows:
Vedanta Biosciences Granted Three U.S. Patents Broadly Covering
Pharmaceutical Compositions and Methods of Use for Therapeutics
Based on Immune-Modulating Bacterial Consortia
CAMBRIDGE, Massachusetts, May 16, 2017- Vedanta Biosciences,
pioneering the development of a novel class of therapies for immune
and infectious diseases based on rationally designed consortia of
bacteria derived from the human microbiome, today announced that
the United States Patent and Trademark Office (USPTO) has issued
three new patents, 9,642,881, 9,642,882, and 9,649,345. The patents
broadly cover compositions of matter and methods of use for
therapeutic products based on beneficial clostridium bacteria,
further strengthening Vedanta's leading intellectual property
position.
"Our pioneering efforts in the development of therapeutics based
on immune-modulating bacterial consortia are continuing to be
validated through the issuance of additional composition of matter
and method of treatment claims worldwide," said Bernat Olle, Ph.D.,
Chief Executive Officer of Vedanta Biosciences. "The expansion of
our intellectual property estate and, in particular, these new
patents significantly enhance the value proposition for our
pipeline and partnered programs."
The new U.S. patent issuances provide additional support for
several programs in Vedanta's pipeline, including therapies for the
treatment of Inflammatory Bowel Disease (IBD) and other autoimmune
and infectious diseases. They also build on earlier patent
issuances from the USPTO, European Patent Office (EPO), and Japan
Patent Office (JPO) to further enhance Vedanta's global
intellectual property portfolio.
About Vedanta Biosciences
Vedanta Biosciences, a subsidiary of PureTech Health (LSE: PRTC;
www.puretechhealth.com), is pioneering development of a novel class
of therapies for immune and infectious diseases based on rationally
designed consortia of bacteria derived from the human microbiome,
with clinical trials expected to begin in 2017. Founded by PureTech
Health and a group of world-renowned experts in immunology and
microbiology, Vedanta Biosciences is a leader in the microbiome
field with capabilities to discover, develop and manufacture drugs
based on live bacterial consortia. Leveraging its proprietary
technology platform and the expertise of its team of scientific
co-founders, Vedanta Biosciences has isolated a vast collection of
human-associated bacterial strains and characterised how the immune
system recognises and responds to these microbes. This work has led
to the identification of human commensal bacteria that induce a
range of immune responses - including induction of regulatory T
cells and Th17 cells, among others - as well as the
characterisation of novel molecular mechanisms of microbial-host
communication. These advances have been published in leading
peer-reviewed journals including Science, Nature (multiple), Cell
and Nature Immunology. Vedanta Biosciences has harnessed these
biological insights as well as data from clinical translational
collaborations to generate a pipeline of programs in development
for infectious disease, autoimmune disease, inflammation and
immune-oncology. The clinical potential of therapeutic manipulation
of the microbiome has been validated by multiple randomised,
controlled trials in infectious disease and inflammatory bowel
disease. Vedanta Biosciences has a leading global intellectual
property portfolio in the microbiome field with patents issued by
the European Patent Office (EPO), Japan Patent Office (JPO) and the
United States Patent and Trademark Office (USPTO), and through
patent families exclusively licensed worldwide to Vedanta under an
agreement with the University of Tokyo.
Vedanta Biosciences' scientific co-founders have pioneered the
fields of innate immunity, Th17 and regulatory T cell biology, and
include Dr. Ruslan Medzhitov (Professor of Immunobiology at Yale),
Dr. Alexander Rudensky (tri-institutional Professor at the Memorial
Sloan-Kettering Institute, the Rockefeller University and Cornell
University), Dr. Dan Littman (Professor of Molecular Immunology at
NYU), Dr. Brett Finlay (Professor at the University of British
Columbia) and Dr. Kenya Honda (Professor, School of Medicine, Keio
University). Vedanta is backed by PureTech Health, Seventure,
Invesco Asset Management, and Rock Springs Capital.
About PureTech Health
PureTech Health (PureTech Health plc, PRTC.L) is an advanced,
clinical-stage biopharmaceutical company developing novel medicines
that modulate the adaptive human systems. PureTech's therapies
target the dysfunctions in the immune, nervous, and
gastro-intestinal systems by addressing the underlying
pathophysiology of disease from a systems perspective rather than
through a single receptor or pathway. The Company is advancing a
rich pipeline that includes multiple human proof-of-concept studies
and pivotal or registration studies expected to read out over the
next 12-18 months. PureTech Health's growing research and
development pipeline has been developed in collaboration with some
of the world's leading scientific experts, who along with
PureTech's experienced team and a stellar Board identify, analyse
and advance very selectively the opportunities the Company believes
hold the most promise for patients. This experienced and engaged
team places PureTech Health at the forefront of ground-breaking
science and technological innovation and leads the Company between
and beyond existing disciplines. For more information, visit
www.puretechhealth.com or connect with us on Twitter
@puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
PureTech Health FTI Consulting
Allison Mead Ben Atwell, Matthew
+1 617 651 3156 Cole, Rob Winder
amead@puretechhealth.com +44 (0) 20 3727
1000
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRADDGDULXBBGRU
(END) Dow Jones Newswires
May 16, 2017 02:01 ET (06:01 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From May 2024 to Jun 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2023 to Jun 2024